Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565397156> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2565397156 endingPage "e14554" @default.
- W2565397156 startingPage "e14554" @default.
- W2565397156 abstract "e14554 Background: DCF is associated with a high response rate in gastroesophageal cancer (GE), fact that makes it an interesting schedule in the neoadjuvant treatment. We developed a modified DCX (mDCX) regimen trying to minimize toxicity without compromising efficacy. We report the initial results of pathological response and toxicity. Methods: Patients (pts) with resectable adenocarcinoma of the stomach, gastroesophageal junction (GEJ) or lower esophagus (T3, T4 or N+) assessed by echoendoscopy and CT received 3 pre and 3 postoperative cycles of mDCX (docetaxel 70 mg/m2 day 1, cisplatin 70mg/m2 day 1 and capecitabine 1,500 mg/m2/day x 14 days, q21 days) with 3 doses of prophylactic GCSF (Neopugen 300mg) on day 4, 6 and 8 of every cycle. Results: Between July 2007 and July 2010, 26 pts (17 male/9 female) were treated in a Spanish centre. Median age: 54 years (range, 44-72). KPS: 80% (70-90%). Site of tumor: 15 stomach/8 GEJ/3 esophagus. Clinical stage of tumor: 2 (II)/ 12 (IIIA)/12 (IIIB). Surgery was curative in all patients and took place 8 weeks after completing the 3rd cycle; postoperative chemotherapy was initiated in 7 weeks (range: 5-10) after surgery. 22 (85%) pts of the 25 ones that had completed preoperative chemotherapy received surgery (1 pt requested to interrupt the treatment). The incidence of postoperative complications was 23% (6 pts) and there were 2 deaths (9%) within 10 days due to sepsis and esophageal fistula (graft necrosis). 3 of the 22 pts (14%) did not complete three postoperative cycles due to toxicity. The incidence of grade 3-4 pre and postoperative toxicity was 19% and 67%, respectively and 27% needed a dose reduction. Grade 3/4 adverse events: nausea/vomiting (40%), neutropenia (27%), diarrhea (19%), skin effects (8%). Toxicity-related hospitalizations: 27%. There were 2 (9%) complete pathological responses, 12 (54%) downstaging and 2 progressive diseases. Conclusions: Modified DCX seems to be tolerable, feasible and efficient. This regimen warrants further development in the neoadjuvant setting of GE cancer." @default.
- W2565397156 created "2017-01-06" @default.
- W2565397156 creator A5021915064 @default.
- W2565397156 creator A5022716889 @default.
- W2565397156 creator A5029623776 @default.
- W2565397156 creator A5049943675 @default.
- W2565397156 creator A5050526128 @default.
- W2565397156 creator A5066828645 @default.
- W2565397156 creator A5067182334 @default.
- W2565397156 creator A5074198867 @default.
- W2565397156 creator A5076059050 @default.
- W2565397156 creator A5079246466 @default.
- W2565397156 date "2011-05-20" @default.
- W2565397156 modified "2023-10-18" @default.
- W2565397156 title "A phase II study with perioperative modified docetaxel, cisplatin, and capecitabine (mDCX) in resectable gastroesophageal adenocarcinoma." @default.
- W2565397156 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e14554" @default.
- W2565397156 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28020722" @default.
- W2565397156 hasPublicationYear "2011" @default.
- W2565397156 type Work @default.
- W2565397156 sameAs 2565397156 @default.
- W2565397156 citedByCount "2" @default.
- W2565397156 countsByYear W25653971562012 @default.
- W2565397156 countsByYear W25653971562019 @default.
- W2565397156 crossrefType "journal-article" @default.
- W2565397156 hasAuthorship W2565397156A5021915064 @default.
- W2565397156 hasAuthorship W2565397156A5022716889 @default.
- W2565397156 hasAuthorship W2565397156A5029623776 @default.
- W2565397156 hasAuthorship W2565397156A5049943675 @default.
- W2565397156 hasAuthorship W2565397156A5050526128 @default.
- W2565397156 hasAuthorship W2565397156A5066828645 @default.
- W2565397156 hasAuthorship W2565397156A5067182334 @default.
- W2565397156 hasAuthorship W2565397156A5074198867 @default.
- W2565397156 hasAuthorship W2565397156A5076059050 @default.
- W2565397156 hasAuthorship W2565397156A5079246466 @default.
- W2565397156 hasConcept C121608353 @default.
- W2565397156 hasConcept C126322002 @default.
- W2565397156 hasConcept C141071460 @default.
- W2565397156 hasConcept C2776694085 @default.
- W2565397156 hasConcept C2777297899 @default.
- W2565397156 hasConcept C2777819096 @default.
- W2565397156 hasConcept C2777909004 @default.
- W2565397156 hasConcept C2778239845 @default.
- W2565397156 hasConcept C2779134260 @default.
- W2565397156 hasConcept C2779742542 @default.
- W2565397156 hasConcept C2779920096 @default.
- W2565397156 hasConcept C2781182431 @default.
- W2565397156 hasConcept C2781190966 @default.
- W2565397156 hasConcept C2781413609 @default.
- W2565397156 hasConcept C31174226 @default.
- W2565397156 hasConcept C43270747 @default.
- W2565397156 hasConcept C526805850 @default.
- W2565397156 hasConcept C71924100 @default.
- W2565397156 hasConcept C90924648 @default.
- W2565397156 hasConceptScore W2565397156C121608353 @default.
- W2565397156 hasConceptScore W2565397156C126322002 @default.
- W2565397156 hasConceptScore W2565397156C141071460 @default.
- W2565397156 hasConceptScore W2565397156C2776694085 @default.
- W2565397156 hasConceptScore W2565397156C2777297899 @default.
- W2565397156 hasConceptScore W2565397156C2777819096 @default.
- W2565397156 hasConceptScore W2565397156C2777909004 @default.
- W2565397156 hasConceptScore W2565397156C2778239845 @default.
- W2565397156 hasConceptScore W2565397156C2779134260 @default.
- W2565397156 hasConceptScore W2565397156C2779742542 @default.
- W2565397156 hasConceptScore W2565397156C2779920096 @default.
- W2565397156 hasConceptScore W2565397156C2781182431 @default.
- W2565397156 hasConceptScore W2565397156C2781190966 @default.
- W2565397156 hasConceptScore W2565397156C2781413609 @default.
- W2565397156 hasConceptScore W2565397156C31174226 @default.
- W2565397156 hasConceptScore W2565397156C43270747 @default.
- W2565397156 hasConceptScore W2565397156C526805850 @default.
- W2565397156 hasConceptScore W2565397156C71924100 @default.
- W2565397156 hasConceptScore W2565397156C90924648 @default.
- W2565397156 hasIssue "15_suppl" @default.
- W2565397156 hasLocation W25653971561 @default.
- W2565397156 hasOpenAccess W2565397156 @default.
- W2565397156 hasPrimaryLocation W25653971561 @default.
- W2565397156 hasRelatedWork W1990715504 @default.
- W2565397156 hasRelatedWork W2007796202 @default.
- W2565397156 hasRelatedWork W2324380568 @default.
- W2565397156 hasRelatedWork W2359668509 @default.
- W2565397156 hasRelatedWork W2362476736 @default.
- W2565397156 hasRelatedWork W2393915849 @default.
- W2565397156 hasRelatedWork W2424785541 @default.
- W2565397156 hasRelatedWork W3013628089 @default.
- W2565397156 hasRelatedWork W3030235090 @default.
- W2565397156 hasRelatedWork W3031689446 @default.
- W2565397156 hasVolume "29" @default.
- W2565397156 isParatext "false" @default.
- W2565397156 isRetracted "false" @default.
- W2565397156 magId "2565397156" @default.
- W2565397156 workType "article" @default.